Can we expect additional Rx's to the fold this winter?It's been a while and I've had some time to digest several variables; here are some of my findings:
These guys are still trading well below cash, which is interesting. According to their most recent 10-Q, they had about $135MM in cash (after the $45MM financing). After looking at their pipeline timeline and respective indications, the next catalyst occurs in late November (rVVC); furthermore, there remains a potential Hansoh Pharma payment (don't forget, they can earn up to $112MM in milestone payments) in FY2023, and an EU partner agreement. If the latter is consummated, they may not need further financing. We'll see if they can deliver.
Insofar as recurrent VVC, it appears that with the sNDA, if approved, might provide up to an additional 540K Rx's to the fold. Here's an outdated corroborative article illustrating some numbers vis-a-vis rVVC (my guess is that today, the numbers are higher)...
https://today.wayne.edu/medicine/news/2018/07/03/new-study-shows-138-million-women-suffer-from-recurrent-candida-or-yeast-vaginitis-numbers-expected-to-increase-30164
Cheers,
JJ